Research
Hormonal
SGLT-2 inhibitors provide kidney protection (slowing eGFR decline, reducing albuminuria) but have limited or no impact on body weight, making them distinct from GLP-1s in treating obesity-related kidney disease.
SGLT-2 inhibitors protect the kidneys by slowing function decline and reducing protein in urine. They are not primarily weight-loss drugs, so they should be used alongside lifestyle changes for obesity.
GoodQualifiesHIGH confidence
Pharmacological interventions, such as sodium-glucose co-transporter 2 inhibitors... provide kidney protection but have limited or no impact on body weight.
Why this rating
Based on multiple studies and meta-analyses cited in the review.
Source
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
Frederik Flindt Kreiner et al. · Biomedicines · 2023
DOI 10.3390/biomedicines11092498
narrative_reviewCited 33×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is an independent risk factor for the onset and progression of chronic kidney disease (CKD), with visceral adiposity and fatty kidney disease serving as key pathophysiological mediators.Good
- GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss and reduce albuminuria, offering potential kidney protection, though their direct impact on eGFR decline in normal-functioning kidneys is not yet fully established.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →